Search Browse Earnings

Theriva Biologics, Inc. — SlamSEC

Theriva Biologics, Inc.

NYSE:TOVX

Pharmaceutical Preparations·ROCKVILLE, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Shallcross Steven A

Revenue

$2.6M

FY 2011

Adj. EBITDA

-$21.3M

-814.7% margin

FY 2024

Net Income

-$19.7M

-753.1% margin

FY 2023

EPS (Diluted)

-$28.48

FY 2024

Stock Price

$0.18

+0.4%

2026-03-11

52W Range

$0.16 – $1.50

P/E Ratio

-0.0x

Market Cap

$6.0M

Cash

$23.2M

FY 2024

Total Debt

$219,000

FY 2024

Net Cash

$23.0M

FY 2024

Enterprise Value

-$16.9M

Debt / EBITDA

1.1x

FY 2011

EV / EBITDA

0.8x

Employees

—